Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance

Oncogene volume 21, pages 4000–4008 (2002)Cite this article

Abstract

The estrogen receptor alpha (ERα) signaling plays an essential role in breast cancer progression and endocrine therapy. Mitogen-activated protein kinase (MAPK/Erk1/2) has been implicated in ligand-independent activation of ER, resulting in the cross-talk between growth factor and ER mediated signaling. In this study, we examined the effect of the cross-talk on estradiol (E2)-mediated signaling, tumor growth and its effect on anti-estrogen therapy. Our findings demonstrate that expression of constitutively activated mitogen activated kinase kinase (MEK1), an immediate upstream activator of MAPK in estrogen receptor positive MCF-7 breast cancer cells (MEK/MCF-7), showed an increase in ERα-driven transcriptional activation. In MEK/MCF-7 cells maximal transactivation levels were achieved in response to treatment with much lower E2 concentrations (10−10 M E2) when compared to MCF-7 control cells (10−8 M E2). Furthermore, we have seen an increased association between ERα and its nuclear coactivators AIB1 or TIF-2, in MEK/MCF-7 cells relative to those seen in MCF-7 control cells. In addition, in vivo studies show that MEK/MCF-7 cell tumors are ∼threefold larger than those of MCF-7 cell, in the presence of E2. Immunohistochemical staining demonstrates that progesterone receptor (PR) and pS2, two E2-regulated gene products, are significantly increased in MEK/MCF-7 cell tumors compared to those of MCF-7 control tumors, suggesting that activation of ERα by MAPK enhances the expression of E2-regulated genes and accelerates tumor growth. Remarkably, the antiestrogens tamoxifen and ICI 182,780, were shown both in vitro and in vivo studies to efficiently antagonize the stimulatory effects of E2 on ER regulated transactivation and tumor growth in MEK/MCF-7 as well as MCF-7 cell lines. Taken together, these data suggest that MAPK/ER cross-talk enhances ERα-mediated signaling and accelerates E2-dependent tumor growth without diminishing sensitivity to the inhibitory effects of anti-estrogens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Ali S, Metzger D, Bornert JM, Chambon P . 1993 EMBO J. 12: 1153–1160

  • Anderson E, Clarke RB, Howell A . 1998 J. Mam. Gland Biol. Neoplasia 3: 23–35

  • Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK . 1992 Breast Cancer Res. Treat. 24: 85–95

  • Bunone G, Briand PA, Miksicek RJ, Picard D . 1996 EMBO J. 15: 2174–2183

  • Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H . 2001 J. Biol. Chem. 276: 9817–9824

  • Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A, Auricchio F . 1999 EMBO J. 18: 2500–2510

  • Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF, Korach KS . 1996 Proc. Natl. Acad. Sci. USA 93: 12626–12630

  • Danielian PS, White R, Lees JA, Parker MG . 1992 EMBO J. 11: 1025–1033

  • El-Tanani MK, Green CD . 1997 J. Steroid Biochem. Mol. Biol. 60: 269–276

  • Fan JD, Wagner BL, McDonnell DP . 1996 Mol. Endocrinol. 12: 1605–1616

  • Font de Mora J, Brown M . 2000 Mol. Cell. Biol. 20: 5041–5047

  • Gee JM, Robertson JF, Ellis IO, Nicholson RI . 2001 Int. J. Cancer 95: 247–254

  • Gonzalez FA, Raden DL, Davis RJ . 1991 J. Biol. Chem. 266: 22159–22163

  • Green S, Chambon P . 1988 Trends Genet. 4: 309–314

  • Henttu PM, Kalkhoven E, Parker MG . 1997 Mol. Cell. Biol. 4: 1832–1839

  • Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS . 1996 Endocrinology 137: 1735–1744

  • Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA . 1993 Mol. Endocrinol. 7: 992–998

  • Joel PB, Traish AM, Lannigan DA . 1995 Mol. Endocrinol. 9: 1041–1052

  • Joel PB, Traish AM, Lannigan DA . 1998 J. Biol. Chem. 273: 13317–13323

  • Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al . 1995 Science 270: 1491–1494

  • Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J . 1998 Oncology 55: (Suppl 1) 5–10

  • Kondapaka SB, Fridman R, Reddy KB . 1997 Int. J. Cancer 70: 722–726

  • Krust A, Green S, Argos P, Kumar V, Walter P, Bornert JM, Chambon P . 1986 EMBO J. 5: 891–897

  • Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P . 1987 Cell 51: 941–951

  • Kumar V, Green S, Staub A, Chambon P . 1986 EMBO J. 5: 2231–2236

  • Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL . 2000 Cancer Res. 60: 5887–5894

  • Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E . 1995 Endocrinology 136: 164–171

  • Lees JA, Fawell SE, Parker MG . 1989 Nucleic Acids Res. 17: 5477–5488

  • Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ . 2001 J. Biol. Chem. 276: 22177–22182

  • Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG . 1994 Science 265: 966–970

  • Metzger D, Ali S, Bornert JM, Chambon P . 1995 J. Biol. Chem. 270: 9535–9542

  • Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW . 1999 Proc. Natl. Acad. Sci. USA 96: 1858–1862

  • O'Malley BW, Tsai SY, Bagchi M, Weigel NL, Schrader WT, Tsai MJ . 1991 Recent Prog. Horm. Res. 47: 1–24

  • Rowan BG, Weigel NL, O'Malley BW . 2000 J. Biol. Chem. 275: 4475–4483

  • Sivaraman VS, Wang H, Nuovo GJ, Malbon CC . 1997 J. Clin. Invest. 99: 1478–1483

  • Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ . 2002 Mol. Endocrinol. 16: 116–127

  • Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ . 2001 Cancer Res. 61: 5985–5991

  • Tari AM, Lopez-Berestein G . 2000 Int. J. Cancer 86: 295–297

  • Tora L, Gronemeyer H, Turcotte B, Gaub MP, Chambon P . 1988 Nature 333: 185–188

  • Welch DR, Sakamaki T, Pioquinto R, Leonard TO, Goldberg SF, Hon Q, Erikson RL, Rieber M, Rieber MS, Hicks DJ, Bonventre JV, Alessandrini A . 2000 Cancer Res. 60: 1552–1556

  • Xu L, Glass CK, Rosenfeld MG . 1999 Curr. Opin. Genet. Dev. 9: 140–147

  • Yee D, Lee AV . 2000 J. Mam. Gland Biol. Neoplasia 5: 107–115

Download references

Acknowledgements

We thank Dr Natalie Ahn (University of Colorado, Boulder, CO, USA) for providing activated MEK cDNA. This research is supported by funds from NIH grants (CA 64248 and CA 83964) to KB Reddy.

Author information

Author notes

  1. Natasha Atanaskova and Venkateshwar G Keshamouni: N Atanaskova and VG Keshamouni contributed equally to this work

Authors and Affiliations

  1. Department of Pathology, Wayne State University School of Medicine, 540 E. Canfield, Detroit, 48201, Michigan, MI, USA

    Natasha Atanaskova, Venkateshwar G Keshamouni, Joseph S Krueger, Fred Miller & Kaladhar B Reddy

  2. Department of Physiology, Wayne State University School of Medicine, 540 E. Canfield, Detroit, 48201, Michigan, MI, USA

    Janice A Schwartz

Authors
  1. Natasha Atanaskova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Venkateshwar G Keshamouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph S Krueger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Janice A Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fred Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kaladhar B Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaladhar B Reddy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atanaskova, N., Keshamouni, V., Krueger, J. et al. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21, 4000–4008 (2002). https://doi.org/10.1038/sj.onc.1205506

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205506

Keywords

This article is cited by

Search

Advanced search

Quick links